Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Iris Lavon is currently the Associate Professor of Neurobiology; She is also the Head of Molecular Neuro-Oncology Laboratory, Neurology Department in Hadassah at Hebrew University Medical Center, Jerusalem, Israel.
The median survival time of patients with glioblastoma is still poor, partly due to a lack of effective treatment. Following our observation that androgen receptor (AR) is amplified in glioblastomas at the DNA, RNA and protein levels, we have investigated in-vitro and in-vivo the potential of androgen receptor (AR) as a new therapeutic target for glioblastoma. AR gene was amplified in 27% of glioblastoma specimens from men (n=22) and 38.2% of women (n=21). AR-RNA was overexpressed (>2 fold) in 93% (n=30), and AR-protein was induced in 56% of the glioblastomas (n=16). Thirty percent of glioblastomas (n=21) also expressed a constitutively active AR-splice-variant lacking the Ligand-Binding-Domain. Furthermore, AR antagonists, bicalutamide and enzalutamide induced a concentration-dependent death in three glioblastoma cell lines. Enzalutamide given orally to nude mice bearing subcutaneous human glioma xenografts resulted in a 72% reduction in tumor volume (p=0.0027). These results suggest involvement of AR signaling in glioblastoma and raise it as a new potential therapeutic target for this devastating disease.